Addressing Bioanalysis in Clinical Trials during COVID-19
We want to know how the COVID-19 pandemic has impacted your work so we can bring up these results for discussions at our upcoming Friday Roundtable Event on Nov. 6 and share the general status of the industry on how these challenges have been handled.
Email *
1. Did you have to change your traditional bioanalytical workflows for sample collection, shipment, and analysis? *
If yes, what changes and did they have a major impact on your processes?
2. Did you experience a disruption, delays of reagents, lab or medical supplies? *
If Yes, what were these interruptions?
3. Did you experience delays or disruptions on the enrollment or site closures during your clinical trials? *
If yes, what types of COVID-19 impacts have you experienced?
4. Did you have to or will you try to use non-validated PK/ADA assays for or any other type of filing package for COVID-19 or any other therapeutics? *
If you did, was it accepted by the Health Authority?
Clear selection
5. Did you explore the option of banking samples and testing later acceptable for EUA, BLA or any other type of filing with regulatory agencies? *
If you did, was it acceptable to the Health Authority?
Clear selection
Your organization/company *
Submit
Never submit passwords through Google Forms.
This form was created inside of bioinsidernetwork.com. Report Abuse